By Bill Berkrot(Reuters) - An experimental once-weekly medicine for type 2 diabetes developed by Eli Lilly and Co proved as effective in lowering blood sugar as Victoza from Danish drugmaker Novo Nordisk in an eagerly anticipated late stage study.The Lilly drug, dulaglutide, achieved the primary goal of the 599-patient study by demonstrating so-called non-inferiority to the highest approved dose of Victoza after 26 weeks, according to initial results released by the company on Tuesday.
CHICAGO (AP) — New research suggests that half of all U.S. adults have diabetes or pre-diabetes.The study of government health surveys echoes previous research and shows numbers increased substantially between 1988 and 2012 although they mostly leveled off after 2008. Overall, 12 percent to 14 percent of adults had diagnosed diabetes in 2012, the latest data available. Most of that is Type 2 diabetes, the kind linked with obesity and inactivity.
Eli Lilly and Co (LLY) won the US Food and Drug Administration’s (FDA) approval yesterday for its latest diabetes medication, Trulicity. The drug will be used as a supplement for the treatment of type-2 diabetes in adults, and will require exercise and diet control. However, due to safety concerns, the approval comes with a clause that requires Eli Lilly to conduct post-marketing studies to establish Trulicity’s safety profile.
NEW DELHI: Three new type-2 diabetes medicines, two of which were recently launched in India, have come under the scanner of the US drug regulator for potential risk of causing acidosis that could require hospitalization. The US Food and Drug Administration (FDA) has warned medical professionals and patients that type-2 diabetes medicines - canagliflozin, dapagliflozin, and empagliflozin - may cause high levels of blood acids which can lead to serious adverse effects.
Biogen Idec Inc’s (NASDAQ:BIIB) Alzheimer’s drug candidate, BIIB037, showed promise in its Phase Ib testing, so much so that the company has decided to push the drug directly into Phase III trials, skipping Phase II trials, the company announced early morning Tuesday at the 2014 Deutsche Bank BioFEST Conference.
Mylan Inc. (MYL) has become a tough competitor in the biosimilar glargine race after announcing that it will begin Phase-III trials to show the non-inferiority of its experimental drug glargine when compared to Sanofi SA’s (SNY) diabetes drug Lantus.
Lantus generated revenue of $7.6 billion in fiscal year 2013. It and Mylan’s experimental drug will be used to treat type 2 diabetes mellitus patients.
Hundreds of scientists sifting through genetic data from 122,000 people have quintupled the number of gene variants known to boost the risk of diabetes, a pair of studies released Sunday reported.A consortium of researchers first isolated 10 gene mutations that help determine the body's ability to regulate blood sugar and insulin levels, the key factors underlying type 2 diabetes.